AI Article Synopsis
- A 50-year-old woman visits the emergency department with an itchy rash on her trunk and felt unwell for two days.
- Despite normal lab results, her frequent use of a new whirlpool led doctors to suspect a Pseudomonas folliculitis infection.
- A culture confirmed the presence of Pseudomonas aeruginosa, and treatment involved topical disinfectants, resulting in healing without complications.
Article Abstract
An Itching Pleasure A 50-year-old female patient presents in the emergency department with an itchy, acneiform exanthema on the trunk and malaise for two days. Laboratory testing showed no abnormalities. After further questioning, the patient reported frequent use of her new whirlpool. Based on the medical history and the clinic we suspected a pseudomonas folliculitis. A bacterial culture of the pustules showed growth of Pseudomonas aeruginosa, which confirmed the diagnosis. Systemic antibiotics were not necessary in the absence of risk factors for severe progress or immunosuppression. The exanthema healed within a few days without any complications by using external disinfectants.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1024/1661-8157/a003426 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adverse event of ruxolitinib cream: a real-world analysis based on FDA adverse event reporting system from 2021 to 2024.
Expert Opin Drug Saf
December 2024
Department of Dermatology, Third Xiangya Hospital, Central South University, Changsha, China.
Background: Ruxolitinib cream, a topical Janus kinase (JAK) inhibitor, is a widely used treatment for various dermatological diseases. This study employs the FDA Adverse Event Reporting System (FAERS) database to examine adverse events (AEs) associated with ruxolitinib cream.
Methods: This study employed disproportionate analysis methods, including reported odds ratio and proportional reporting ratio, to collate AEs reported from the fourth quarter of 2021 to the first quarter of 2024.
English version of clinical practice guidelines for the management of atopic dermatitis 2024.
J Dermatol
December 2024
Medical Informatics and Management, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
This is the English version of the 2024 clinical practice guidelines for the management of atopic dermatitis (AD). AD is a disease characterized by relapsing eczema with pruritus as a primary lesion. A crucial aspect of AD treatment is the prompt induction of remission via the suppression of existing skin inflammation and pruritus.
View Article and Find Full Text PDFPrimary Biliary Cholangitis: personalizing second-line therapies.
Hepatology
November 2024
Department of Medicine, Division of Gastroenterology and Hepatology, University of California Davis School of Medicine, Sacramento, California, USA.
Article Synopsis
- Primary biliary cholangitis (PBC) is an autoimmune disease primarily affecting middle-aged women, characterized by damage to small bile ducts, leading to liver issues like cholestasis and cirrhosis.
- The main treatment for PBC has been ursodeoxycholic acid, which helps slow disease progression but doesn't alleviate symptoms; new second-line therapies are being developed for patients who don't respond well.
- Recent medications like obeticholic acid, elafibranor, and seladelpar show promise in improving liver function and reducing cholestasis, while considerations for personalized treatment based on patient features are essential.
Cutaneous adverse events due to checkpoint inhibitors - a retrospective analysis at a tertiary referral hospital in Switzerland 2019-2022.
Front Oncol
December 2024
Department of Medicine, Cantonal Hospital Lucerne, Lucerne, Switzerland.
Introduction: Checkpoint inhibitors are increasingly important in anti-cancer treatment. Therefore, knowledge of immune-related cutaneous adverse events (ir-cAE) is crucial for therapy management and continuation.
Objective: The study aimed to analyze the incidence of cutaneous adverse events caused by checkpoint inhibitor therapy, including their clinical presentation, management, and impact on further treatment.
Resolution of Erythema Annulare Centrifugum With Lung Cancer Drug Therapy: A Case Report.
Cureus
November 2024
Department of Dermatology, Japanese Red Cross Akita Hospital, Akita, JPN.
Tumor-associated erythema annulare centrifugum is commonly observed in leukemia and lymphoma. In this case, we reported erythema annulare centrifugum associated with lung cancer that resolved following targeted drug therapy. A 71-year-old man with psoriasis visited our hospital with erythema annulare and pruritus.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!